Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 61.09 |
| Open | 61.00 |
| Bid | 61.60 x 1200 |
| Ask | 61.80 x 1800 |
| Day's range | 60.82 - 61.71 |
| 52-week range | 57.17 - 74.12 |
| Volume | |
| Avg. volume | 7,168,125 |
| Market cap | 77.265B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 18.84 |
| EPS (TTM) | 3.27 |
| Earnings date | 26 Oct 2022 - 31 Oct 2022 |
| Forward dividend & yield | 2.92 (4.78%) |
| Ex-dividend date | 14 Sept 2022 |
| 1y target est | 69.96 |
- Motley Fool
2 Reasons This Beaten-Down Stock Could Be About to Rebound
Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.
- Simply Wall St.
What Kind Of Investors Own Most Of Gilead Sciences, Inc. (NASDAQ:GILD)?
Every investor in Gilead Sciences, Inc. ( NASDAQ:GILD ) should be aware of the most powerful shareholder groups...
- Business Wire
Gilead Sciences to Acquire MiroBio
FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
